Compare SPXC & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPXC | IBRX |
|---|---|---|
| Founded | 1912 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.2B |
| IPO Year | 1994 | 2015 |
| Metric | SPXC | IBRX |
|---|---|---|
| Price | $146.08 | $5.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $234.00 | $14.25 |
| AVG Volume (30 Days) | 715.2K | ★ 12.5M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.08 | ★ 38.71 |
| EPS | ★ 4.35 | N/A |
| Revenue | ★ $2,265,100,000.00 | $113,288,000.00 |
| Revenue This Year | $22.70 | $99.98 |
| Revenue Next Year | $16.24 | $108.29 |
| P/E Ratio | $35.48 | ★ N/A |
| Revenue Growth | 14.17 | ★ 668.31 |
| 52 Week Low | $137.86 | $1.95 |
| 52 Week High | $251.08 | $12.43 |
| Indicator | SPXC | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.54 | 32.96 |
| Support Level | $137.86 | N/A |
| Resistance Level | $244.82 | $8.62 |
| Average True Range (ATR) | 7.79 | 0.56 |
| MACD | 0.07 | -0.26 |
| Stochastic Oscillator | 29.15 | 8.93 |
SPX Technologies Inc supplies engineered heating, ventilation, and air conditioning, or HVAC, products, as well as detection and measurement technologies and power equipment. The company operates through two reportable segments. The HVAC segment which generates the majority of the revenue for the company, designs, manufactures, installs, and services cooling products, as well as heating and ventilation products. The Detection and Measurement technologies segment designs, manufactures, and installs underground pipe and cable locators and inspection equipment, bus-fare collection systems, and others. Geographically, the company has its operations in the United States, Canada, China, the United Kingdom, and Others. It derives maximum revenue from United States.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.